Abstract. Wc investigated a role for Hedgehog signalling in glioblastoma, neuroblastoma and medulloblastoma by studying the transcription ol PTCH, SMO, GUI and GU3 in a total of 25 cell lines by standard RT-PCR and qRT-PCR, before and after 5-a7.a-2'-deoxycytidine and trichostatin A (TSA) treatments. Also 25 glioblastoma samples were tested by qRT-PCR. We also performed real-time methylated specific PCR (qMSP) of the SMO promoter region in DNA from 80 tumor sainples (40 glioblastomas and 40 neuroblastomas) and from the 25 cell lines. We detected SMO promoter methylation in more than half of the cell lines and tumor samples. PTCH expression in cell lines was lower than in normal controls, just the opposite to GUI. SMO and GU3 expression were high and fully correlated in glioblastoma and medulloblastoma, although partially in neuroblastoma. Our results support the existence of Hedgehog signalling in glioblastoma and medulloblastoma, and to a lesser extent, in neuroblastoma.
Introduction
Genes of the Bmi-1, Notch, Wnt and Sonic Hedgehog (Shh) pathways are crucial for development and may also be involved in stem cell regeneration. The Shh pathway regulates the embryonic development of both invertebrates and vertebrates, and contributes to the formation of different organs and tissues, including the neural tube. Shh is a secreted protein relea.sed from Purkinje cells, being responsible for the patterning, polarity and development of the cerebellum. It binds to target cells presenting the twelve transmembrane receptor Patched (Ptch), prompting cell growth and proliferation. Shh deregu-lated expression leads to developmental abnormalities and tumor formation as m the case of pancreatic. colorectal, breast and prostate cancer, basal cell carcinoma and brain tumors, including medullobla.stoma (1) . The first evidence for Shh roles in tumorigenesis came from a patient suffering froin Gorlin's Syndrome, a kind of familial predisposition to medulloblastoma, rhabdomyosarcoma and basal cell carcinoma (2) .
In the absence of Shh, Ptch inhibits the seven transmembrane receptor Smoothened (Smo) (3) . Shh-Ptch binding relieves Smo, that further activates the downstream target Glil, and Patch itself (4.5). The GU gene family was first identified in glioblastoma (6) . GUI, GU2 and GU3 share five highly conserved tandem C2H2 zinc finger domains and a histidinecysteine linker sequence in between the zinc fingers. In humans. GUI has two isoforms, GU2 has three alternatively spliced exons, and GUS has only one isoform. Glil acts as an activator, Gli2 as an activator or as a repressor depending upon its catalytic activity, and Gli3 as a repressor (7) (8) (9) (10) (11) .
It has recently been reported that functional Smo is required for GU3 expression in colorectal carcinoma cell lines and that SMO methylation leads to silence of GU3 expression independently of the Shh pathway (12) . In order to prove this in malignant brain tumors, we selected 25 cell lines (6 of medulloblastoma, 8 of glioblastoma, and 11 of neuroblastoma) and 80 tumor samples (40 glioblastomas and 40 neuroblastomas) to check for PTCH, GUI, SMO and GU3 expression, together with SMO methylation. The expression was checked by standard RT-PCR and qRT-PCR and compared with normal adult brain RNA as a positive control. After treating the cell lines with 5-aza-2'-deoxycytidine and TSA (trichostatin A), mRNA expression was newly checked. We also checked SMO promoter methylation by real-time melting curve (qMSP) analysis in both tumor samples and cell lines.
Materials and methods
Cell lines and tumor samples. Twenty-five cell lines (6 from medulloblastoma, 8 from glioblastoma and 11 from neuroblastoma), together with 80 tumor samples (40 glioblastomas and 40 neuroblastomas) were analyzed in this study. For a complete list of the cell lines, see Table III . Medulloblastoma and glioblastoma cells were maintained in RPMI-1640 medium (Gibco/Invitrogen) supplemented with 10% fetal calf serum, 1 % penicillin and 0.1 % amphocin. For medulloblastoma cells, 4% non-essential amino acids were added. Neuroblastoma cell lines were maintained in DMEM medium (Gibco/Invitrogen) SHAHI el at HEDGEHOG SIGNALLING (N BRAIN TUMORS Primers used for standard RT-PCR (s), qRT-PCR (q) or both (s,q). SMO~M and SMO-U were used as mcthylation primers (M) and unmethylation primers (U) for qiMSP. T", annealing temperature; bp, ba.se pairs of tiic amplified produet. 
5-aza-2'-deoxycytidine and TSA treatments of cells.
Treatments of cells in culture were started when the confluence was about 30% (2.6x10' cells/ml). Five micrograms of 5-aza-2'-deoxycytidine (Sigma-Aldrich) was used for 72 h, and 100 ng/ ml TSA (Sigma-Aldrich) was applied for the next 24 h. Cell media were changed every 24 h. RNA extraction was performed before and after treatments with 5-aza-2'-deoxycytidine and TSA, in order to perform cDNA synthesis, RT-PCR and qRT-PCR of PTCH, SMO and GU3 and to compare their expression levels in the two conditions.
Bisulphite modification, amplification and melting curve analysis. We selected the SMO promoter region for MSP analysis (13) Table III ). The rest of the neuroblastoma cell lines (7 of 11) expressed only SMO The glioblastoma cell line U87MG only expressed GLI3. Most of the medulloblastoma, glioblastoma and neuroblastoma cell lines showed lower expression of PTCH than normal adult brain RNA controls (Fig. 1 ) After 5-azd-2'-deoxycytidine and TSA treatments PTCH exptession was increased (Fig. 3 , Table III) All 25 cell lines a.ia 25 glioma samples expressed GLIi at substantial quantity in comparison to normal controls (Fig. 1) .
SMO promoter methylatwn. Four medulloblastoma cell lines (PFSK-1, TE671c2, D283 and SK-PN-DW) presented an inci-ease in exptessidn of the SMO gene after 5-aza-2 - 
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deoxycytidine and TSA treatments (Fig. 3) . Also, the glioblastoma cell line U87MG and two neuioblastoma cell lines [SK-N-FJ and Be(2)cJ presented re-expression of the gene after the treatments (Fig. 3) . The melting curves supported a partial/ hemimethylation status at the SMO promoter (Fig. 4 ) In order to corroborate this result in tumor samples. 40 glioblastomas and 40 neuroblastomas were studied by qMSP and melting curve analysis (Fjig.,4).,pf these;,|2;4 gl^pblas,tQrnas (60%), ^(^ lj6 neu):9blastpn^as,,(4p^;)| j)i^p;ile^ yieth^l^licjp^.yfj parfial/hef]y;iJ9fl^ylati.9n,,pf the^N^ geng,pron;iQ^€r region^jy 1' ''i iit.r,-) \u( I, ),i CI '
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Before 5'Aza After S'Azii Before S'Aza After S'Aza Before 5Ai« In this sense, in studies.on medulloblastoma, neuroblastoma and supratentorial PNET it is worthwhile to define specific genetic markers, that allow a, more accurate diagnosis and a more specific treatment of these relatively similar lessions. Embryologically speaking, glioblastoma and medulloblastoma derive from the neuroepithelium, while neuro-: blastema from the neural crest, as other tumors that appear outside of the nervous system (melanoma, thyroid medullary carcinoma, small cell lung cancer, malignant schwannoma, among others). The Shh pathway is an evolutionarily conserved developmental cassette, leading different tasks in the developing organism, such as the development of the neural tube, craniofacial structures, limb, lung, and others, to ensure proper positional or polarity information within part of the developing embryo. The activation of the Shh pathway is conducted through Shh, which triggers a derepression of the negative modulation of the pathway executed by Ptch on Smo. The net effect of Shh binding to the cell surface complex is an activation of the pathway by downstream activators such as GUI.
Wc have checked the expression of some of the major Shh pathway genes [PTCH, SMO, GUI and GLI3) in medulloblastoma. neuroblastoma and glioblastoma cell lines, together with glioblastoma and neuroblastoma samples. Methylation studies were applied on SMO as well.
All medulloblastoma cell lines (except DAOY) and all glioblastoma cell lines (except GOS-3) shov>cd higher levels of expression of GIJI than in normal adult brain RNA expression. However, only . Expression of GLI3 in all medulloblastoma and glioblastoma cell lines and in almost all glioblastoma samples (except two samples) was higher than in normal adult brain RNA. However, similar results were obtained in only 4 out of 11 neuroblastoma cell lines (SK-N-MC, MC-IXC, SK-N-DZ and IMR-32).
We have demonstrates that the Shh pathway is activate(f| in medulloblastoma, glioblastoma and neuroblastoma. Prfeviousiy-; the activation <>f this rpaitfeW-a^^iiiniedwlloblastoiin*:' wa^'jkhd'wn (^4); bW, it is Mtya-MiyuMliWteod wfrfethe!f '' activation 0bhq,Slihipatlwa)fi.,.',;:^ ' -.'.C • ..x^,v'J, .iV;-;;i/ M :i,;i It was reported that high expression of PTCH implies the Shh pathway iictivation in tumors ofvthe digestives tr.act<17). In our study PTCH expression was lower than in'normal controls, but PrC/^'xa-'-expression after treatments'wi^5-aza-2'-deox'^ycytidine and TSA supports its promoter methylation, as • demonstrated for breast cancer (20) .
In this' study, we paid special attention to the relationship between the expresion of SMO and GLI3, as they act together, oncC the Shh pathway has been initiated, to make the expression of GUI possible. Qncc this is initiated, a cascade of genes taking part in apoptosis control and regulation of growdi will be activated. Smo behaves as aii oncogene, as its activation by Shir promotes Glil activation. On the contrary. Gli3 exerts a dual possibility; as an activator (similarly to Glil and GIi2), or as a repressor (21) that brakes the activating function of Smo on Glil. . - We demonstrated that SMO acts as an activator of the Shh pathway in medulloblastoma, glioblastoma and neuroblastoma, as we detected a good level of expresion of SMO in most cell lines and tumor samples studied. We also demonstrated the methylation of SMO promoter in cell lines and tumors, and the fact that expression of SMO increases after 5-aza-2'-deoxycytidine and TSA treatments in cell lines. Nevertheless it seems methylation is not pl-aying a significant role in silencing this gene.
Medulloblastoma and glioblastoma cell lines showed a very noticcble correjation, between SMO upAtGUS RT-PCR expression, with the exception of the U87MG glioblastoma cell line, which did'nbt shb\V a clear expression level ot SMO, although after treating ttie cell'line with 5-aza-2'-deoxycytidine and TSA, re-expresion of SMO was observed. These results were confirmed by qRT-PCR analysis before and after treatments with demethylating agents, and by qMSP that revealed melting curves compatible with partial/hemimethylation of SMO in the U87MG cell line.
Contrary to medulloblastoma and glio^astoma, neuroblastoma cell lines did not show a clear correlation between SMO and GU3 expression. Seven of 11 (64%)'cell lines presented SMO expression but did.iKit expresSc^L/5iTwo of these 7 cell lines did not even express GU3 after treatme^s with 5-aza-2'-deoxycytidine and TSA, while the other 5i did. The rest of the cell lines (4 of 1 l,_3|(^)_,gtowed_W^ artd GU3 expression. qMSP also supported SAfO promofes'partial/hemimethylation in neuroblastoma cell lines and tumor samples.
After the analysis of SMO and GU3 expression we concluded that SMO gene expression seems to be required for GU3 expression in medulloblastoma and glioblastoma, as shown by the clear correlation of expression of both genes in these types of brain tumors, and that Gli3 is acting as an activator of the Shh pathway in these tumors. On the contrary, neuroblastomas present different results, as the correlation between SMO and GU3 expression is seen in only 4 of 11 cell lines.;In these cases, we would equally suggest Gli3 as an activator of Shh. But the other 7 cell lines present a different scenario: 5 of them 're-express GLI3 after the treatments with 5-aza-2'-deoxycytidine and TSA, which even ^WggestsijiBls :c6m]Mertttd for/TCWyittiat GL/5. might?be sub-: 'jitiSt^a'l6[iifrbiihi6if'i^&iy\i^^^ its owil'expfessi6n;'mdep^ Mili. T*He fact tliat' ih thfi" .a,tlj?r..2,,fie}l,J,ipic;^,flo,e^pifp^sipi) .is:fpr(>diLiced"even..after the treatments with 5-aza-2'-deoxycytidine and TSA indicates a non-activator but a repressor function for Gli3 in at least a subset of neuroblastomas. Also a gradient-like expression of other genes, SMO included e.g., might be needed for GLIS expression, in an Shh-dependent or -independant'mana^,.!' 'i
The fact that a clear activation of the Shh pathway has been demonstrated by our study in glio-blastoma and medulloblastoma, but not clearly enough in neuroblastoma, suggests different embiyological ethiology of these tumors, as they arc neuroepithelial in origin, while neuroblastoma derives from the neural crest. This embryological difference might irt'part explain the differences in the involvement of the l^nh'^deinonstrated in oui^ ktudy ifdr these three malignant tumors of the nervous Sytcm. Further' studfes afe required to evaluate our hypothese
